Basilea Pharmaceutica AG (LON: 0QNA)

Market Cap	428.91M
Revenue (ttm)	131.22M
Net Income (ttm)	-574.12K
Shares Out	n/a
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29
Average Volume	2,385
Open	39.40
Previous Close	39.90
Day's Range	39.40 - 39.55
52-Week Range	32.20 - 51.30
Beta	0.74
RSI	39.90
Earnings Date	Feb 18, 2025

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumoni...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 147
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QNA

Financial Performance

In 2023, Basilea Pharmaceutica AG's revenue was 157.63 million, an increase of 6.68% compared to the previous year's 147.77 million. Earnings were 10.45 million, a decrease of -13.96%.

Financial numbers in CHF